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We agree completely with Davidson et al that valid comparison of hazards ratios (HRs) for different continuous measures requires that the units of both variables are comparable. In our earlier paper, 1 we reported HRs per 10 mm Hg and per 1-SD increment and found no appreciable difference in the prediction of coronary heart disease (CHD) risk by either method. In the recent paper, 2 we reported only per 10 mm Hg, which we felt was more easily understood by clinicians.
We also agree that the question of relative importance cannot be addressed by the HRs, but should be addressed by comparison of test statistics, or significance levels, obtained when each variable is added to the same model. Whether one compares Ϫ2 log likelihood statistics, or the asymptotically equivalent Wald chi-squared statistics, makes little difference in large samples. From comparisons of chi-squared statistics in our 2001 paper 2 (Table 2) , we note that diastolic pressure is more "important" among subjects under 50 years old, whereas pulse pressure is (somewhat) more "important" than systolic pressure in subjects aged 60 years and older.
As for recalculation of HRs to 1-SD increment in our 2001 paper, 2 data are shown in Table 1 that permit one to perform the calculations, albeit crudely, for each age group: multiply by SD/10 the ␤ estimated per 10 mm Hg to obtain the estimate per 1 SD, then exponentiate. For subjects aged 60 years and older, one obtains HRϭ1.40 for SBP, HRϭ1.12 for DBP, and HRϭ1.43 for PP. The test statistics are invariant to location and scale changes on the variables, so inference about relative importance is unaffected.
The conclusion that pulse pressure is superior to systolic blood pressure in predicting CHD risk in individuals 60 years and older requires further elaboration. Pulse pressure cannot replace systolic blood pressure as a single measure of CHD risk. 3 The best clinical strategy for using blood pressure indices for the estimation of CHD risk in older persons is to first determine the level of SBP elevation and then adjust the overall risk upward if there is wide pulse pressure, ie, discordantly low diastolic blood pressure. 3 However, it remains premature to change national treatment recommendations, because any new strategy of blood pressure assessment must first be tested directly in clinical trials.
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